Azmain Alamgir

This paper develops programmable protein degraders (uAbs) that selectively knock down pathogenic β-catenin in vitro and in vivo, reducing tumor cell survival and proliferation.

This paper develops lipid nanoparticles for intracellular antibody delivery, showing efficacy in inhibiting cytosolic targets in cancer and disease models.

This study uses lipid nanoparticles to deliver peptide-based degraders, enabling targeted protein degradation in cancer cells and demonstrating reduced target levels in mice.